Bioprinting specialist Jellatech announced the successful development of a triple-helical, bioidentical and functional full-length human collagen produced from a proprietary cell line. This announcement comes just eight months after Jellatech unveiled its cell-based bovine collagen.
“This milestone further demonstrates that our platform technology for efficiently producing high quality collagen is translatable across multiple cell types, which allows us to address a broad market need for collagen”, comments Rob Schutte, Head of Science.
Human collagen is used in numerous biomedical and clinical applications, including tissue engineering, arthritis treatment, regenerative medicine, dermal fillers and 3D bioprinting.
“We are extremely proud and excited to announce the expansion of our protein portfolio with human collagen. Human collagen is such an important step in our journey to make a positive impact”, says Stephanie Michelsen, Founder & CEO.
Jellatech is now seeking funding opportunities to expand production and advance commercialization. Given the wide range of applications for Jellatech’s proteins, the company is also seeking partnerships, collaborations and strategic synergies to accelerate the delivery of reliable and sustainable collagen to the world.
Find out more about Jellatech at jellatech.com.